{
  "symbol": "SUPN",
  "company_name": "Supernus Pharm",
  "ir_website": "https://www.supernus.com/Investors",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.supernus.com/press-releases",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Press Releases \n\nNews Category Financial ReleasesGeneral Releases\n\nYear None2024202320222021202020192018201720162015201420132012201120102009200820072006\n\n2024\n\nDate | Title  \n---|---  \nNovember 26, 2024  |  [Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference](/news-releases/news-release-details/supernus-participate-36th-annual-piper-sandler-healthcare) |  [PDF Version](/node/14791/pdf) PDF Version  \nNovember 13, 2024  |  [Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference](/news-releases/news-release-details/supernus-pharmaceuticals-participate-2024-jefferies-london) |  [PDF Version](/node/14776/pdf) PDF Version  \nNovember 4, 2024  |  [Supernus Announces Third Quarter 2024 Financial Results](/news-releases/news-release-details/supernus-announces-third-quarter-2024-financial-results) |  [PDF Version](/node/14691/pdf) PDF Version  \nOctober 31, 2024  |  [Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024](/news-releases/news-release-details/supernus-presents-promising-data-open-label-phase-2a-study-spn) |  [PDF Version](/node/14681/pdf) PDF Version  \nOctober 21, 2024  |  [Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results](/news-releases/news-release-details/supernus-pharmaceuticals-host-conference-call-and-webcast) |  [PDF Version](/node/14651/pdf) PDF Version  \nOctober 17, 2024  |  [Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder](/news-releases/news-release-details/supernus-announces-promising-data-open-label-phase-2a-study-spn) |  [PDF Version](/node/14641/pdf) PDF Version  \nOctober 10, 2024  |  [Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder](/news-releases/news-release-details/supernus-pharmaceuticals-host-webcast-review-open-label-phase-2a) |  [PDF Version](/node/14631/pdf) PDF Version  \nSeptember 24, 2024  |  [Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree](/news-releases/news-release-details/busy-philipps-encourages-women-take-charge-their-adhd-fall) |  [PDF Version](/node/14606/pdf) PDF Version  \nSeptember 19, 2024  |  [Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit](/news-releases/news-release-details/supernus-pharmaceuticals-participate-td-cowen-4th-annual-novel) |  [PDF Version](/node/14596/pdf) PDF Version  \nAugust 28, 2024  |  [Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference](/news-releases/news-release-details/supernus-pharmaceuticals-participate-2024-wells-fargo-healthcare) |  [PDF Version](/node/14571/pdf) PDF Version  \n  \nDisplaying 1 - 10 of 26 \n"
        }
      ]
    },
    {
      "section_name": "Events and Presentations",
      "links": [
        {
          "title": "Events and Presentations",
          "url": "https://ir.supernus.com/events-and-presentations",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Events & Presentations \n\n##  Upcoming Events \n\nDate | Event Details  \n---|---  \nDecember 4, 2024 at 12:00 PM EST  |  36th Annual Piper Sandler Healthcare Conference [Listen to webcast](https://event.webcasts.com/starthere.jsp?ei=1697248&tp_key=4ee7e604df) [Add to Outlook](/node/14796/ics) [Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Supernus%20Pharmaceuticals%20-%2036th%20Annual%20Piper%20Sandler%20Healthcare%20Conference&dates=20241204T170000Z/20241204T170000Z&details=Event%20Details%3A%20http%3A//ir.supernus.com/events/event-details/36th-annual-piper-sandler-healthcare-conference%0A%0AWebcast%3A%20https%3A//event.webcasts.com/starthere.jsp%3Fei%3D1697248&tp_key=4ee7e604df&location=&trp=false&sprop=name%3A)  \n  \nPresentations \n\nTitle  \n---  \n[Supernus Corporate Overview ](/static-files/bf26ef67-f84e-4d4e-a334-f32d06e3d03f) 1.84 MB  \n  \n##  Archived Events \n\nDate | Event Details  \n---|---  \nNovember 20, 2024 at 4:30 PM EST  |  [Jefferies London Healthcare Conference](/events/event-details/jefferies-london-healthcare-conference-1) [Listen to webcast](https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=supn&url=https%3A//wsw.com/webcast/jeff315/supn/1882104)  \nNovember 4, 2024 at 4:30 PM EST  |  [Supernus Pharmaceuticals 3Q 2024 Financial and Business Update Conference Call](/events/event-details/supernus-pharmaceuticals-3q-2024-financial-and-business-update-conference-call) [Listen to webcast](https://edge.media-server.com/mmc/p/ipjmw5z5)  \nOctober 17, 2024 at 4:30 PM EDT  |  [Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder](/events/event-details/supernus-pharmaceuticals-host-webcast-review-open-label-phase-2a-study-spn-820) [Listen to webcast](https://edge.media-server.com/mmc/p/kffjmghf/) Supporting Materials [View Presentation](/static-files/ab65cf23-b874-4b16-819b-13eb197962e7 \"820P202 Topline Slide _Webcast draft 1015 Final & Approved.pdf\") 614.1 KB\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "https://ir.supernus.com/corporate-governance",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Corporate Governance \n\nThe Board of Directors of Supernus Pharmaceuticals, Inc. (the \"Company\") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.\n\nCommittee Charters \n\nTitle  \n---  \n[Audit Committee Charter](/static-files/ba5ac9f6-db9f-400d-a085-f4a4b6f93059)  \n[Compensation Committee Charter](/static-files/2bd3a9e3-2cbb-43db-8dc4-2a832becee14)  \n[Governance and Nominating Committee Charter](/static-files/0d62117a-c035-4a53-9196-0cfe3ca351ae)  \n  \nOther Governance Documents \n\nTitle  \n---  \n[Policy Statement on Securities Trades by Directors, Officers and Employees](/static-files/df3d2ac3-2384-49b8-afc5-862897bacd62)  \n[Payments to Physicians](/static-files/30703210-d33a-481d-94d8-71dc9441aa50)  \n[Majority Voting and Director Resignation Policy](/static-files/33a5fd3a-1119-4288-b49a-d03cb4f02c75)  \n[California Compliance Declaration](/static-files/8bed7383-42fd-4805-b7f4-4ac6522eff5d)  \n[Corporate Governance Guidelines](/static-files/33096b04-921e-4a6e-9297-fea2ae801e17)  \n[Code of Ethics](/static-files/896fc967-1d4f-403a-86a8-cbcb175e5f99)  \n[Audit Committee Procedures for Handling Complaints](/static-files/0f2e3e1a-b8ed-4470-8a21-0fd35225cba6)  \n[Policy Regarding Shareholder Communications with Directors](/static-files/1b13bf6e-fcb1-4004-8cd3-0b0d9ee3c49f)\n"
        }
      ]
    },
    {
      "section_name": "Financials and Filings",
      "links": [
        {
          "title": "Financials and Filings",
          "url": "https://ir.supernus.com/financial-information",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Financials & Filings \n\n[Show all](#)\n\n2024 \n\nQ3\n\n  * [Supernus Pharmaceuticals 3Q 2024 Financial and Business Update Conference Call](/events/event-details/supernus-pharmaceuticals-3q-2024-financial-and-business-update-conference-call)\n\n  * [Supernus Announces Third Quarter 2024 Financial Results](/news-releases/news-release-details/supernus-announces-third-quarter-2024-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001356576-24-000067)\n\n\n\n\n2023 \n\nQ1\n\n  * [Supernus Announces First Quarter 2023 Financial Results](/news-releases/news-release-details/supernus-announces-first-quarter-2023-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001356576-23-000034)\n\n\n\n\n## Annual Reports\n\nDocuments  \n---  \n  \n  * Add Files [2023 Annual Report](/static-files/4e9d1452-56a0-463b-94ee-70a4e035297b \"Supernus 2023 AR.pdf\") 738.1 KB\n\n  \n  \n  * Add Files [2022 Annual Report](/static-files/c7601889-ced1-4343-ae2e-e26edfede8d9 \"Supernus Pharmaceuticals Inc_ARS_As filed.pdf\") 884.2 KB\n\n  \n  \n  * Add Files [2021 Annual Report ](/static-files/de7b436c-7319-419c-bc6a-a80ef2715821 \"Annual 10-K Report FY 2021.pdf\") 1.1 MB\n\n  \n  \n## Proxy Statements\n\n[Filing date ](?field_nir_sec_form_group_target_id%5B491%5D=491&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | View  \n---|---  \nApril 29, 2024 |  [0001104659-24-054023.pdf](/static-files/6ba94d9e-430a-4ca1-b442-fc1fb788134e) [0001104659-24-054023.rtf](/static-files/f089ea58-bff8-4709-9d87-5f65bab43d27) [0001104659-24-054023.xls](/static-files/7c9c8dc0-0028-4776-ae9f-216e2fb9b722) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/def-14a/0001104659-24-054023) [View HTML](/node/14336/html)  \nApril 29, 2024 |  [0001104659-24-054024.pdf](/static-files/c534f726-baf8-44ea-aea6-2421e2e29080) [0001104659-24-054024.rtf](/static-files/7723e69d-7c8b-48e3-bc55-2539208b9038) [View HTML](/node/14331/html)  \n  \n## Form 10-K\n\n[Filing date ](?field_nir_sec_form_group_target_id%5B471%5D=471&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | View  \n---|---  \nApril 29, 2024 | [View HTML](/node/14341/html) [0001104659-24-054028.pdf](/static-files/94056a66-df35-4402-af47-a5ddfff57be3) [0001104659-24-054028.rtf](/static-files/a4e4a05d-80fe-47dd-b8a8-cce6e2095fdf)  \nFebruary 27, 2024 | [View HTML](/node/14156/html) [0001356576-24-000013.pdf](/static-files/2fce4136-7e7d-4016-a1ea-5b75f5282f21) [0001356576-24-000013.rtf](/static-files/b1ec60df-9598-4761-99f6-ce595b9d19d3) [0001356576-24-000013.xls](/static-files/7ce3b4ff-5056-4937-8267-3257ce3c4538) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001356576-24-000013)  \n  \n## Form 10-Q\n\n[Filing date ](?field_nir_sec_form_group_target_id%5B496%5D=496&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | View  \n---|---  \nNovember 4, 2024 |  [0001356576-24-000067.pdf](/static-files/e9a2b660-8362-428d-910b-328ee0bd8725) [0001356576-24-000067.rtf](/static-files/5832595d-3ee6-48f5-8607-9c18a8978d8d) [0001356576-24-000067.xls](/static-files/38ad4742-776b-496c-be86-592e44d0b8f1) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001356576-24-000067) [View HTML](/node/14701/html)  \nAugust 6, 2024 |  [0001356576-24-000051.pdf](/static-files/0f7057e4-20ad-4bbd-9605-b6548347e719) [0001356576-24-000051.rtf](/static-files/91b09d59-e71b-443d-b331-81aeede5c73f) [0001356576-24-000051.xls](/static-files/986f0107-017f-4069-9093-11d6d881e9c2) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001356576-24-000051) [View HTML](/node/14536/html)\n"
        }
      ]
    }
  ]
}